Detalhe da pesquisa
1.
AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models.
Cancer Cell Int
; 19: 346, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31889898
2.
Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
J Virol
; 89(22): 11457-72, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26339063
3.
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
Retrovirology
; 10: 43, 2013 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-23602046
4.
Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.
Antimicrob Agents Chemother
; 56(3): 1331-41, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22203605
5.
Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization.
Antimicrob Agents Chemother
; 56(8): 4365-74, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22664975
6.
Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model.
J Clin Immunol
; 32(5): 1082-92, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22476912
7.
HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.
J Virol
; 85(9): 4330-42, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21345957
8.
Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.
J Virol
; 85(13): 6353-68, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21507963
9.
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
Retrovirology
; 8: 89, 2011 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-22054077
10.
Knockdown of USP18 increases α 2a interferon signaling and induction of interferon-stimulating genes but does not increase antiviral activity in Huh7 cells.
Antimicrob Agents Chemother
; 55(9): 4311-9, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21709085
11.
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
N Engl J Med
; 359(14): 1442-55, 2008 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-18832245
12.
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
J Infect Dis
; 201(6): 803-13, 2010 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20151839
13.
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
Antimicrob Agents Chemother
; 54(10): 4451-63, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20660667
14.
Use of a highly sensitive strand-specific quantitative PCR to identify abortive replication in the mouse model of respiratory syncytial virus disease.
Virol J
; 7: 250, 2010 Sep 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-20860795
15.
Inhibitors of viral entry.
Handb Exp Pharmacol
; (189): 177-202, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19048201
16.
Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
PLoS One
; 13(12): e0204099, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30586365
17.
Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
AIDS Res Hum Retroviruses
; 33(12): 1220-1235, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28797170
18.
Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors.
Antiviral Res
; 67(3): 121-40, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16112209
19.
CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.
Antivir Chem Chemother
; 16(6): 339-54, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16329283
20.
Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer.
J Mol Med (Berl)
; 93(6): 619-31, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25940316